Yuyu Pharma said Thursday that it has signed a deal with Novartis Korea to exclusively supply the latter's five prescription drugs for athlete's foot, dyslipidemia, and epilepsy in Korea.

Under the accord, Yuyu Pharma would supply Lamisil (ingredient: terbinafine hydrochloride) for athlete's foot, Lescol (fluvastatin sodium) for dyslipidemia, and a Tegretol (ingredient: carbamazepine) series for epilepsy to all domestic medical institutes from August.

Lamisil is a prescription drug for athlete's foot, ringworm of the body, jock itch, and fungal infection of the nails.

Novartis' Lescol is prescribed to delay coronary atherosclerosis in patients with primary hypercholesterolemia and coronary artery disease or reduce the risk of recurrence of cardiac accidents after percutaneous coronary intervention.

The Tegretol series include Tegretol CR, Tegretol, and Tegretol Syrup, for treating epilepsy, trigeminal neuralgia, mania, manic depression, and schizophrenia.

"We can now supply medications that meet the needs of health providers depending on the treatment situations with the expanded prescription drug lineup along with our existing products," Yuyu Pharma CEO Yu Won-sang said. "We will continue to carry out various collaborations with our sales and marketing capabilities."